Literature DB >> 33229366

The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases.

Jessica L Turnier1, J Michelle Kahlenberg2.   

Abstract

IFNs are well known as mediators of the antimicrobial response but also serve as important immunomodulatory cytokines in autoimmune and autoinflammatory diseases. An increasingly critical role for IFNs in evolution of skin inflammation in these patients has been recognized. IFNs are produced not only by infiltrating immune but also resident skin cells, with increased baseline IFN production priming for inflammatory cell activation, immune response amplification, and development of skin lesions. The IFN response differs by cell type and host factors and may be modified by other inflammatory pathway activation specific to individual diseases, leading to differing clinical phenotypes. Understanding the contribution of IFNs to skin and systemic disease pathogenesis is key to development of new therapeutics and improved patient outcomes. In this review, we summarize the immunomodulatory role of IFNs in skin, with a focus on type I, and provide insight into IFN dysregulation in autoimmune and autoinflammatory diseases.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33229366      PMCID: PMC7694882          DOI: 10.4049/jimmunol.2000596

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  149 in total

1.  Excision of 3' termini by the Trex1 and TREX2 3'-->5' exonucleases. Characterization of the recombinant proteins.

Authors:  D J Mazur; F W Perrino
Journal:  J Biol Chem       Date:  2001-03-06       Impact factor: 5.157

Review 2.  Recognition of pathogen-associated molecular patterns by TLR family.

Authors:  Shizuo Akira; Hiroaki Hemmi
Journal:  Immunol Lett       Date:  2003-01-22       Impact factor: 3.685

3.  Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus.

Authors:  Stephan Meller; Franziska Winterberg; Michel Gilliet; Anja Müller; Ingrida Lauceviciute; Juliane Rieker; Norbert J Neumann; Robert Kubitza; Michael Gombert; Erich Bünemann; Ulrike Wiesner; Petra Franken-Kunkel; Holger Kanzler; Marie-Caroline Dieu-Nosjean; Ali Amara; Thomas Ruzicka; Percy Lehmann; Albert Zlotnik; Bernhard Homey
Journal:  Arthritis Rheum       Date:  2005-05

Review 4.  Juvenile Idiopathic Inflammatory Myopathies.

Authors:  Adam M Huber
Journal:  Pediatr Clin North Am       Date:  2018-08       Impact factor: 3.278

5.  A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis.

Authors:  J Aicardi; F Goutières
Journal:  Ann Neurol       Date:  1984-01       Impact factor: 10.422

6.  Selective Janus kinase inhibitors come of age.

Authors:  John J O'Shea; Massimo Gadina
Journal:  Nat Rev Rheumatol       Date:  2019-02       Impact factor: 20.543

7.  A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus.

Authors:  Min Ae Lee-Kirsch; Dipanjan Chowdhury; Scott Harvey; Maoliang Gong; Lydia Senenko; Kerstin Engel; Christiane Pfeiffer; Thomas Hollis; Manfred Gahr; Fred W Perrino; Judy Lieberman; Norbert Hubner
Journal:  J Mol Med (Berl)       Date:  2007-04-18       Impact factor: 5.606

8.  The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types.

Authors:  Herwig P Moll; Thomas Maier; Anna Zommer; Thomas Lavoie; Christine Brostjan
Journal:  Cytokine       Date:  2010-10-12       Impact factor: 3.861

9.  Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Authors:  Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

10.  Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.

Authors:  Joan T Merrill; Richard Furie; Victoria P Werth; Munther Khamashta; Jorn Drappa; Liangwei Wang; Gabor Illei; Raj Tummala
Journal:  Lupus Sci Med       Date:  2018-11-26
View more
  3 in total

1.  Two Duplicated Ptpn6 Homeologs Cooperatively and Negatively Regulate RLR-Mediated IFN Response in Hexaploid Gibel Carp.

Authors:  Jin-Feng Tong; Li Zhou; Shun Li; Long-Feng Lu; Zhuo-Cong Li; Zhi Li; Rui-Hai Gan; Cheng-Yan Mou; Qi-Ya Zhang; Zhong-Wei Wang; Xiao-Juan Zhang; Yang Wang; Jian-Fang Gui
Journal:  Front Immunol       Date:  2021-11-26       Impact factor: 7.561

2.  Single-cell transcriptomics reveals distinct effector profiles of infiltrating T cells in lupus skin and kidney.

Authors:  Garrett S Dunlap; Allison C Billi; Xianying Xing; Feiyang Ma; Mitra P Maz; Lam C Tsoi; Rachael Wasikowski; Jeffrey B Hodgin; Johann E Gudjonsson; J Michelle Kahlenberg; Deepak A Rao
Journal:  JCI Insight       Date:  2022-04-22

Review 3.  Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment.

Authors:  Kyriakos A Kirou; Maria Dall Era; Cynthia Aranow; Hans-Joachim Anders
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.